drugset / Trial / NCT04338724
A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is an open label, dose escalation phase I study to evaluate the clinical safety, tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated Dose (MTD#, if any). This study is composed of two dose level: 1 and 3 mg/kg.
Timeline
- Start
- 2019-12-27
- Primary completion
- 2020-09-21
- Completion
- 2020-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS1002 | Monoclonal antibody | 1 mg/kg | — |
| Subject | CS1002 | Monoclonal antibody | 3 mg/kg | — |